Fred Sammons, DO
Internal Medicine · Knoxville, TNNPI 1114338647
Payments from drug & device makers
Across 228 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Novo Nordisk$647
- AbbVie$448
- Lilly USA, LLC$397
- Amgen$246
- Esperion Therapeutics, Inc.$225
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,709100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 61 | $1,113 |
| Novo Nordisk | 29 | $647 |
| AbbVie(2 entities) | 20 | $448 |
| Lilly USA, LLC | 23 | $397 |
| Amgen | 15 | $246 |
| Esperion Therapeutics, Inc. | 2 | $225 |
| Johnson & Johnson | 13 | $210 |
| Boehringer Ingelheim | 9 | $154 |
| Eisai Inc. | 7 | $138 |
| Bayer | 3 | $136 |
| Novartis | 6 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 5 | $102 |
| Astellas Pharma US Inc | 4 | $83 |
| Portola Pharmaceuticals, LLC | 1 | $57 |
| GSK | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Nevro Corp. | 2 | $45 |
| Edwards Lifesciences | 1 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| AstraZeneca | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Philips North America LLC | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Medtronic | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,709 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $215,345 |
| OzempicSemaglutide | 74 | $131,224 |
| JardianceEmpagliflozin | 79 | $111,140 |
| MounjaroTirzepatide | 72 | $104,096 |
| XareltoRivaroxaban | 75 | $86,996 |
| TrulicityDulaglutide | 23 | $54,539 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 35 | $38,390 |
| Repatha SureclickEvolocumab | 39 | $36,481 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $30,662 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $29,870 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $24,619 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $22,798 |
| FarxigaDapagliflozin Propanediol | 11 | $18,626 |
| Spiriva RespimatTiotropium Bromide | 22 | $16,481 |
| MyrbetriqMirabegron | 21 | $16,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Glyxambi, Spiriva Respimat | $154 | $219,471181 claims |
| PfizerEliquis | $1,113 | $215,345195 claims |
| Lilly USA, LLCMounjaro, Trulicity | $397 | $158,63595 claims |
| Novo NordiskOzempic | $647 | $131,22474 claims |
| Johnson & JohnsonXarelto | $210 | $86,99675 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $46 | $52,73160 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $24,61928 claims |
| AbbVieLinzess, Synthroid | $448 | $20,737197 claims |
| AstraZenecaFarxiga | $32 | $18,62611 claims |
| Astellas Pharma US IncMyrbetriq | $83 | $16,15721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Knoxville
- Amanda Moore MillerKnoxville$2.3M
- George NewmanKnoxville$682K
- Dennis DeruelleKnoxville$263K
- Lewis HagoodKnoxville$143K
- Johnny AltawilKnoxville$23K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.